Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration by Sriram, Krishnan et al.
Thiol Oxidation and Loss of Mitochondrial Complex I Precede
Excitatory Amino Acid-Mediated Neurodegeneration
Krishnan Sriram,1 Susarla K. Shankar,2 Michael R. Boyd,3 and Vijayalakshmi Ravindranath1
Departments of 1Neurochemistry and 2Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore
560 029, India, and 3Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program,
National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201
Human ingestion of “chickling peas” from the plant Lathyrus
sativus, which contains an excitatory amino acid, L-BOAA (L-b-
N-oxalylamino-L-alanine), leads to a progressive corticospinal
neurodegenerative disorder, neurolathyrism. Exposure to
L-BOAA, but not its optical enantiomer D-BOAA, causes mito-
chondrial dysfunction as evidenced by loss of complex I activity
in vitro in male mouse brain slices and in vivo in selected
regions of mouse CNS (lumbosacral cord and motor cortex).
Loss of complex I activity in lumbosacral cord after L-BOAA
administration to mice was accompanied by concurrent loss of
glutathione. The inhibited complex I activity in mitochondria
isolated from lumbosacral cord of animals treated with L-BOAA
rebounded after incubation with the thiol-reducing agent dithio-
threitol, indicating that oxidation of protein thiols to disulfides
was responsible for enzyme inhibition. The inhibition of com-
plex I could be abolished by pretreatment with antioxidant
thiols such as glutathione ester and a-lipoic acid. Chronic
treatment of male mice, but not female mice, with L-BOAA
resulted in loss of complex I activity and vacuolation and den-
dritic swelling of neurons in the motor cortex and lumbar cord,
paralleling the regionality of the aforementioned biochemical
effects on CNS mitochondria. These results support the view
that thiol oxidation and concomitant mitochondrial dysfunction
(also implicated in other neurodegenerative disorders), occur-
ring downstream of glutamate receptor activation by L-BOAA,
are primary events leading to neurodegeneration. Maintenance
of protein thiol homeostasis by thiol delivery agents could
potentially offer protection against excitotoxic insults such as
those seen with L-BOAA.
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L-b-Oxalylaminoalanine (L-BOAA) is a naturally occurring non-
protein amino acid, first isolated from chickling pea obtained
from the plant Lathyrus sativus (Rao et al., 1964) grown in the
drought-prone areas of Africa and Asia. In humans, ingestion of
the chickling pea as a staple diet during famine results in a slowly
progressive, neurodegenerative condition known as neurolathy-
rism (Selye, 1957), a form of motor neuron disease. L-BOAA is
generally considered to be the causative agent in neurolathyrism
(Spencer et al., 1986). Neurolathyrism in humans is characterized
by spastic paraparesis that predominantly targets the Betz cells
and the corticospinal tracts (Ludolph and Spencer, 1996). It is a
highly prevalent neurotoxic disorder (Haimanot et al., 1990) that
predominantly affects males (Roy, 1988). Clinical (Cohn and
Streifler, 1981) and neuropathological studies (Streifler et al.,
1977) have shown the involvement of upper motor neurons,
degeneration of anterior horn cells, and loss of axons in the
pyramidal tracts in the lumbar spinal cord in humans affected by
neurolathyrism.
L-BOAA exposure was first shown to cause seizures in newborn
mice in vivo and degeneration in CNS explant cultures in vitro
(Ross and Spencer, 1987), effects that were abrogated in dose-
dependent manner by known antagonists of a subclass of gluta-
mate receptor, namely, quisqualic receptors. The unique action of
L-BOAA on AMPA receptors was subsequently identified (Ross
et al., 1989), and the ability of the specific AMPA receptor
antagonist NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)
quinoxaline) to prevent L-BOAA-induced neuronal damage con-
firmed that L-BOAA exerted its action through the AMPA re-
ceptors (Pearson and Nunn, 1991). In synaptic membrane
preparations, L-BOAA prevented the binding of [3H]AMPA, and
the ability of L-BOAA to displace [ 3H]AMPA from membranes
prepared from cerebral cortex exceeded that of quisqualic acid or
AMPA itself (Bridges et al., 1988; Ross et al., 1989). Although it
is generally accepted that L-BOAA causes neurodegeneration
through excitotoxic mechanisms, probably involving the AMPA
receptors, the actual molecular mechanisms involved in L-BOAA-
induced neurotoxicity generally remain uncharacterized.
Mitochondrial dysfunction has been implicated in a variety
neurodegenerative disorders. Abnormalities in complex I have
been identified in mitochondria from platelet, brain, and muscle
of Parkinson’s disease patients (Parker et al., 1989; Mizuno et al.,
1995), and cytochrome c oxidase deficiency has been observed in
Alzheimer’s disease brain (Parker et al., 1994). The present
studies indicate that an inhibition of mitochondrial complex I
activity mediated through oxidation of thiol groups in distinctive
regions of the CNS is a primary event in thiol-reversible,
L-BOAA-induced toxicity.
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MATERIALS AND METHODS
Materials. L-BOAA, L-BMAA, AMPA, kainic acid, quisqualic acid, and
MK-801 were obtained from Research Biochemicals (Natick, MA).
NMDA, N-acetyl aspartyl glutamate (NAAG), and glutamic acid were
obtained from Sigma (St. Louis, MO). D-BOAA was procured from
Tocris Neuramin and as a gift from Dr. S. L. N. Rao, Osmania Univer-
sity, Hyderabad, India. NBQX and ubiquinone-1 were gifts from Novo
Nordisk and Eisai Pharmaceutical Company, respectively. Glutathione
isopropyl ester (GSH ester) was obtained as a gift from Yamanouchi
Pharmaceutical Company. All other chemicals and reagents were of
analytical grade and were obtained from Sigma or Qualigens.
Animals. Male and female Swiss albino mice (3–4 months old; 25–30 gm)
or male Wistar rats (3–4 months old, 200–250 gm) were obtained from
National Institute of Mental Health and Neurosciences (NIMHANS)
Animal Research Facility. Animals had access to pelleted diet (Lipton,
Calcutta, India) and water ad libitum.
In vitro studies. Sagittal slices of male mouse or rat brain were
prepared using the previously described apparatus developed in our
NIMHANS laboratory (Pai et al., 1991). Animals were decapitated, and
the brains were quickly removed and kept on a flat surface at 4°C. The
slicer was placed above the brain with equal number of blades on either
side of the median plane and gently pressed. The slices were carefully
transferred using a flat-edged needle to a beaker containing artificial
CSF (ACSF). Four slices of uniform thickness (1 mm) were prepared
from each mouse brain in a time not exceeding 1–2 min. Slices were
incubated in ACSF, pH 7.4, containing sodium chloride (122 mM),
potassium chloride (3.1 mM), calcium chloride (1.3 mM), magnesium
sulfate (1.2 mM), glucose (10 mM), and glycyl glycine (30 mM) in an
oxygen-enriched atmosphere as given by McIlwain (1975) with or with-
out L-BOAA for 1 hr at 37°C.
In experiments performed to evaluate the effects of antioxidant thiols
such as glutathione isopropyl ester (1 mM) or a-lipoic acid (100 mM);
slices were preincubated with the agents for 30 min at 37°C, before
exposure to L-BOAA (1 nM) for 1 hr. To assess the protective effects of
glutamate receptor antagonists on L-BOAA-mediated neurotoxicity, sag-
ittal slices of male mouse brain were prepared from animals dosed 4 hr
earlier with NBQX (30 mg/kg body weight, i.p.) and incubated without
or with L-BOAA (1 nM).
In vivo studies. L-BOAA was dissolved in normal saline (5 or 10 mg/kg
body weight, s.c.) and administered to male and female Swiss albino
mice. Control animals received vehicle alone. The animals were killed at
specified time points, and the brain and spinal cord were removed.
Kidney, heart, lung, and the main lobe of the liver were also removed for
certain experiments. All dissections and tissue handling were performed
at 4°C. The motor cortex (Fig. 1) was dissected out from the brain. The
spinal cord was exposed, and the thoracic cord was collected. The lumbar
and sacral segments of the cord were dissected out together and used for
experiments. In some experiments, the cortex was dissected into three
segments, namely, the frontal and parietal cortex, temporal cortex, and
occipital cortex, following anatomical landmarks. In experiments per-
formed to assess the effect of the AMPA receptor antagonist NBQX,
mice were treated with NBQX (30 mg/kg body weight, i.p., in saline).
After 4 hr, L-BOAA (10 mg/kg body weight, s.c., in saline) was admin-
istered. Control animals received vehicle alone. In some experiments,
the thiol antioxidant a-lipoic acid (20 mg/kg body weight, s.c) was given
0.5 hr before L-BOAA. All animals were killed 24 hr after L-BOAA
injection, and the lumbosacral cord was dissected.
L-BOAA was also administered chronically (5 mg/kg body weight, s.c.,
daily) to male and female mice, and animals were killed after 5, 10, 20,
or 40 d. After 40 d, L-BOAA administration was discontinued and the
animals were killed on the 55th day after the first dose of L-BOAA. The
motor cortex, thoracic, and lumbosacral segments of the spinal cord were
collected for assay of complex I.
Processing of tissue. The tissues (brain slices and cortical regions of
mouse brain or spinal cord segments or other tissue) were processed
immediately for the assay of activities of complex I, complex II, complex
II-III, complex IV, and concentration of glutathione. For the assay of
mitochondrial electron transport complexes, tissues were homogenized
in sucrose (0.25 M) and centrifuged at 1000 3 g for 10 min to obtain a
postnuclear supernatant, which was recentrifuged at 17,000 3 g for 20
min to obtain a crude mitochondrial pellet. The pellet was resuspended
in 0.25 M sucrose and freeze-thawed three times before assay of complex
I (Shults et al., 1995), complex II (Hatefi and Stiggall, 1976), complex
II-III (King, 1967), or complex IV (Gibson and Hill, 1983).
Figure 1. The region from the mouse brain cortical layer (shaded area)
that was dissected out as motor cortex for measurement of enzyme
activity in all subsequent experiments
Figure 2. Effect of L-BOAA on com-
plex I activity in mouse and rat brain
slices. A, Sagittal slices of mouse or rat
brain were incubated in ACSF with
varying concentrations (0.01 pM to 1
mM) of L-BOAA for 1 hr, and the ac-
tivity of complex I was assayed in the
crude mitochondrial preparation. B,
Time-dependent inhibition of complex
I activity by L-BOAA in mouse and rat
brain slices. Sagittal slices of mouse
brain were incubated in ACSF without
(F–F) or with L-BOAA (1 nM, f–f)
for varying intervals (5–60 min), and
the activity of complex I was assayed in
the crude mitochondrial preparation.
The enzyme activity is expressed as
nanomoles of NADH oxidized per
minute per milligram of protein. Val-
ues are mean 6 SEM (n 5 4 – 6
slices). Asterisk s indicate values sig-
nificantly different from respective
control ( p , 0.01).
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Assay of NADH: ubiquinone oxidoreductase (complex I) activity. Com-
plex I activity was assayed in brain mitochondrial preparations as
rotenone-sensitive NADH:ubiquinone-1 oxidoreductase according to
Shults et al. (1995) with minor modifications as described below. The
assay was performed in phosphate buffer (35 mM, pH 7.2) containing
sodium cyanide (2.65 mM), magnesium chloride (5 mM), EDTA (1 mM),
bovine serum albumin (1 mg/ml), and antimycin (2 mg/ml). Brain mito-
chondria (90–150 mg of protein), coenzyme Q-1 (ubiquinone-1, 0.05 mM
final concentration) were added to the assay buffer such that the final
assay volume was 0.48 ml. After preincubation of the reaction mixture at
room temperature for 2 min, the reaction was initiated by the addition of
0.02 ml of a 5 mM solution of NADH. The decrease in absorbance at 340
nm was monitored over time. The assay was also performed in the
presence of rotenone (5 mM final concentration) to determine the
rotenone-insensitive complex I activity. The rotenone-sensitive enzyme
activity was calculated by subtracting the rotenone-insensitive activity
from the total activity and is expressed as nanomoles of NADH oxidized
per minute per milligram of protein.
Estimation of glutathione. For estimation of glutathione, the removed
tissues were frozen immediately in liquid nitrogen and homogenized in
potassium phosphate buffer (100 mM, pH 7.4) containing 1 mM EDTA.
Total glutathione levels were estimated according to the method de-
scribed by Tietze (1969) as follows briefly. To an aliquot of the brain
homogenate, an equal volume of 5-sulfosalicylic acid (1%, w/v) was
added, mixed, and centrifuged at 10,000 3 g for 10 min, and the
supernatant was collected and used for assay of GSH by the enzymatic
recycling method. Another aliquot of the brain homogenate was used for
protein estimation. Protein was estimated by a dye-binding method
(Bradford, 1976). Statistical analyses were performed using Student’s t
test or ANOVA followed by Student–Newman–Keuls, Bonferroni, or
Dunnet’s test.
Histology. Brain and total length of the spinal cord from control and
mice treated with L-BOAA were fixed by perfusion with Bouin’s fixative,
and representative sections were paraffin-embedded, sectioned, and
stained with hemotoxylin and eosin or cresyl violet for Nissl.
Figure 3. Effect of L-BOAA on GSH levels in mouse brain slices ( A) and
effect of GSH on complex I activity inhibited by L-BOAA (B). A, Sagittal
slices of mouse brain were incubated in ACSF without (F–F) and with
L-BOAA (1 nM, E–E) for varying intervals (5–30 min). GSH levels are
expressed as nanomoles of GSH per milligram of protein. Values are
mean 6 SEM (n 5 13–17 slices). B, Mitochondria were prepared from
untreated and L-BOAA-treated mouse brain slices, and complex I activity
was assayed. Two aliquots of this preparation were incubated with and
without GSH (2 mM) for 30 min at 37°C. Thereafter, the activity of
complex I was assayed and expressed as nanomoles of NADH oxidized
per minute per milligram of protein. Values are mean 6 SEM (n 5 5,
wherein each sample was prepared by pooling mitochondria from 3
slices). Asterisks in A and B denote values significantly different from
respective controls ( p , 0.05).
Figure 4. Effect of L-BOAA administration on complex I activity in
different regions of mouse brain cortex ( A), different segments of spinal
cord (B), various regions of brain (C), and in other organs (D) of mice.
Mice were administered a single dose of L-BOAA (10 mg/kg body weight,
s.c.) and killed 0.5 hr after the injection (M). Controls received vehicle
alone (saline, M). Mitochondria prepared from the tissues were used to
measure complex I activity. F/P CT, Frontoparietal cortex; T CT, temporal
cortex; O CT, occipital cortex; C CD, cervical cord; T CD, thoracic cord;
L/S CD, lumbosacral cord; ST, striatum; HP, hippocampus; BS, brainstem;
TH, thalamus; CE, cerebellum; HT, heart; LG, lung; KD, kidney; LV,
liver. Values are mean 6 SEM (n 5 4 animals). Asterisks indicate values
significantly different from respective controls ( p , 0.01).
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RESULTS
In vitro studies
Exposure of sagittal slices of male mouse brain to varying con-
centrations of L-BOAA resulted in a dose-dependent inhibition of
complex I. Incubation of slices with 0.1 pM L-BOAA inhibited
complex I by 28%; at the highest concentration of L-BOAA tested
(1 nM), the enzyme activity was inhibited by ;50% (Fig. 2A).
Complex I was significantly inhibited (17.8% inhibition) within 5
min of exposure to the toxin (Fig. 2B), and, after 60 min of
incubation with L-BOAA, the enzyme activity was inhibited by
51% (Fig. 3). D-BOAA at a similar or even higher concentration
had no effect on complex I activity, indicating the stereospecificity
of the L-isomer in producing toxicity (data not shown).
A marked difference in the response to toxicity was observed
when brain slices prepared from male rats and mice were exposed
to L-BOAA. The minimum toxic dose required to inhibit complex
I significantly in rat brain slices was 1 nM (Fig. 2A), as compared
with the minimum toxic dose of 0.01 pM required to inhibit the
enzyme in mouse brain slices.
To evaluate if L-BOAA had any effect on other mitochondrial
respiratory chain enzymes, thereby contributing to mitochondrial
dysfunction, we assessed the activities of some of these enzymes
in male mouse brain slices incubated with L-BOAA for 1 hr.
L-BOAA (1 nM) significantly inhibited the activities of succinate
dehydrogenase (complex II) and succinate-cytochrome c oxidase
(complex II-III) by 28 and 30%, respectively. The concentration
of L-BOAA at which these enzymes were inhibited was pro-
foundly higher (1 nM) than that required to inhibit complex I (0.01
pM). L-BOAA had no effect on cytochrome c oxidase (complex
IV) activity even at the highest tested concentration (data not
shown).
The neurotoxic effect of L-BOAA (0.1 pM) was compared with
other glutamate agonists: L-glutamic acid (10 mM and 1 mM),
NAAG (0.1 pM and 1 mM), NMDA (1 nM and 1 mM), quisqualic
acid (1 nM and 1 mM), AMPA (100 mM and 1 mM), kainic acid (1
mM and 1 mM), or L-BMAA (1 mM). The lower concentrations of
the agonists selected represent the minimum toxic dose that was
required to induce significant leakage of lactate dehydrogenase
Figure 5. Effect of administration of
varying doses of D-BOAA and
L-BOAA on complex I activity in
mouse brain lumbosacral segment of
spinal cord (A) and motor cortex (B).
Mice were administered varying doses
of D-BOAA or L-BOAA (5 or 10 mg/kg
body weight, s.c). Control animals re-
ceived vehicle alone. The animals were
killed 0.5 hr after administration of
amino acids. The motor cortex ( B) and
lumbosacral cord ( A) were dissected
out and complex I activity was mea-
sured in the mitochondrial prepara-
tion. Values are mean 6 SEM (n 5
3–5 animals). Asterisks indicate val-
ues significantly different from control
( p , 0.05).
Table 1. Comparative toxicities of L-BOAA with other glutamate
agonists
Glutamate agonist Concentration Complex I activity
Control 59.3 6 2.5
L-BOAA 0.1 pM 36.5 6 4.5*
L-glutamic acid 10.0 mM 76.3 6 3.1
1.0mM 25.6 6 4.1*
NMDA 1.0 nM 53.3 6 2.9
1.0 mM 57.0 6 3.5
Quisqualic acid 1.0 nM 47.2 6 3.5
1.0 mM 69.3 6 7.7
AMPA 0.1mM 54.4 6 1.6
1.0mM 37.2 6 8.0*
Kainic acid 1.0 mM 70.2 6 2.4
1.0mM 65.3 6 6.7
L-BMAA 1.0mM 56.7 6 2.6
Sagittal slices of mouse brain were incubated in ACSF without and with L-BOAA or
other glutamate agonists. The complex I activity is expressed as nanomoles of
NADH oxidized per minute per milligram of protein. Values are mean 6 SEM (n 5
4–23 slices). Asterisks indicate values significantly different from control ( p , 0.05).
Statistical analysis was performed using ANOVA followed by Bonferroni’s test or
Dunnet’s test.
Table 2. Effect of glutamate receptor antagonist and thiol antioxidants
on L-BOAA-induced neurotoxicity
Complex I activity
Control 100.0 6 4.5
L-BOAA (1 nM) 67.3 6 3.5*
Control, NBQX 83.5 6 3.2
NBQX 1 L-BOAA 87.3 6 4.8
Control, ALA (100 mM) 77.2 6 3.4
L-BOAA 1 ALA 84.9 6 3.2
Control, GSH ester (1 mM) 91.6 6 6.2
L-BOAA 1 GSH ester 99.3 6 5.9
Sagittal slices of mouse brain were prepared from animals pretreated with NBQX
and incubated in ACSF without and with L-BOAA (1 nM). Two additional sets of
sagittal slices of untreated mouse brain were preincubated with either GSH ester (1
mM) or a-lipoic acid (ALA, 100 mM) for 30 min, after which L-BOAA (1 nM) was
added to one set of slices. Simultaneously, slices without any pretreatment were
incubated under similar incubation conditions. The activity of complex I (% control)
is expressed as nanomoles of NADH oxidized per minute per milligram of protein.
Values are mean 6 SEM (n 5 6–13 slices). Asterisks indicate values significantly
different from corresponding control ( p , 0.05).
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from the slices into the medium (Pai and Ravindranath, 1993). In
addition, higher concentrations (10- to 100-fold) of these agonists
were also tested to determine their effect on mitochondrial func-
tion. Only glutamic acid and AMPA significantly inhibited com-
plex I, albeit at millimolar concentrations; the other agonists
tested had no effect on complex I activity at any of the concen-
trations tested (Table 1).
Exposure of male mouse brain slices to L-BOAA (1 nM) re-
sulted in a small, transient decrease (8.7%) of the endogenous
thiol antioxidant GSH 10 min after incubation with the toxin (Fig.
3A). The GSH levels recovered to control values within 15 min
and were not significantly different from controls at all other time
points. To determine whether the loss in complex I activity was
caused by oxidation of protein thiols, mitochondria prepared
from L-BOAA-treated slices were incubated without and with
GSH (2 mM). In mitochondrial incubations containing GSH,
complex I activity was restored, whereas in incubations with
buffer alone, the enzyme activity remained inhibited (Fig. 3B),
suggesting the involvement of thiol oxidation as a cause of com-
plex I inhibition by L-BOAA.
To determine the mechanism of complex I inhibition by
L-BOAA, experiments were designed to assess if previous expo-
sure to thiol antioxidants could protect against L-BOAA neuro-
toxicity. Pretreatment of male mouse brain slices with GSH
isopropyl ester (1 mM) 0.5 hr before exposure to the toxin (1 nM)
protected against L-BOAA-mediated inhibition of complex I (Ta-
ble 2). Similarly, pretreatment with a-lipoic acid (100 mM) also
afforded protection, indicating that inhibition of complex I may be
caused by the loss of thiol homeostasis (Table 2). The AMPA
receptor antagonist NBQX also afforded protection against
L-BOAA-mediated inhibition of complex I in mouse brain slices
(Table 2).
In vivo studies
In male mice given a single dose of L-BOAA (10 mg/kg body
weight, s.c.), selective loss of mitochondrial complex I activity was
observed in the frontoparietal cortex (Fig. 4A, wherein the motor
cortex is located, Fig. 1) and the lumbosacral segment of the
spinal cord (Fig. 4B) within 0.5 hr after administration. Complex
I activity was not significantly decreased (Fig. 4A–D) in other
brain regions (temporal and occipital cortex, striatum, hippocam-
pus, brainstem, thalamus, and cerebellum), other segments of
spinal cord (cervical and thoracic cord) and in non-CNS tissue
(heart, lung, kidney, and liver). In all further experiments, the
area depicted in Figure 1 was designated as motor cortex and was
dissected out for biochemical estimations.
Administration of the optical antipode of the glutamate ago-
nist, namely, D-BOAA (5 and 10 mg/kg body weight, s.c.) to male
mice resulted in no change in complex I activity in either lumbo-
sacral region of the spinal cord or motor cortex (Fig. 5A,B,
respectively). In contrast, administration of the same dose of
L-BOAA resulted in significant inhibition of complex I activity in
both regions of the CNS within 0.5 hr. Although the enzyme
activity in the motor cortex was inhibited (Fig. 5B) after admin-
istration of the lower dose of L-BOAA (5 mg/kg body weight), the
activity in the lumbosacral cord was affected only after adminis-
tration of higher dose of the glutamate agonist (Fig. 5A).
When we followed the effect of L-BOAA on complex I activity
in motor cortex and lumbosacral cord over a time period, a
striking difference was noticed. A sustained loss of enzyme activ-
ity (Fig. 6B) was observed in the lumbosacral cord after a single
dose of L-BOAA (10 mg/kg body weight), whereas in the motor
cortex, the enzyme activity was inhibited at 0.5 hr after the dose,
but rebounded at 1 hr and returned to near normal levels by 4 hr.
However, at the end of 24 hr, complex I activity remained inhib-
ited (Fig. 6A). Under the same conditions, the enzyme activity in
the thoracic segment of the cord was unaffected. Complex I
activity was also unaffected in the hippocampus and striatum
after L-BOAA administration (5 or 10 mg/kg body weight).
Complex II activity in both motor cortex and spinal cord was
inhibited only 4 and 1 hr after the L-BOAA dose, respectively,
while remaining unaffected in the thoracic cord. Thus, inhibition
of complex II was observed several hours after the inhibition of
complex I (data not shown).
We measured the total GSH content and complex I activity in
Figure 6. Complex I activity and GSH
concentration in the motor cortex (A)
and lumbosacral cord ( B) at various
time periods after a single dose of
L-BOAA. Mice were administered
L-BOAA (10 mg/kg body weight, s.c.),
whereas control animals received vehi-
cle alone. The animals were killed at
indicated time periods. The motor cor-
tex (A) and the lumbosacral segment of
the spinal cord (B) were dissected out
and used for the assay of complex I (in
mitochondrial preparation) or GSH (in
tissue homogenate). The control values
were similar at all time points exam-
ined. Values are mean 6 SEM (n 5 4
animals). Asterisks indicate values sig-
nificantly different from corresponding
control ( p , 0.05).
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motor cortex (Fig. 6A) and lumbosacral cord (Fig. 6B) over a 24
hr period after a single dose of L-BOAA (10 mg/kg body weight).
A small but significant decrease in GSH levels was seen in the
motor cortex at 0.5 and 1 hr after the administration of L-BOAA.
The GSH levels, thereafter, were similar to control levels. Inter-
estingly, in the motor cortex, the complex I activity showed a
transient decrease 0.5 hr after L-BOAA dose, and thereafter
rebounded to enzyme activity higher than controls, however,
after 24 hr, complex I activity in the motor cortex was significantly
lower than controls, indicating that a single dose of L-BOAA
resulted in a long-term inhibition (Fig. 6A). In the lumbosacral
region of the spinal cord, sustained loss of both complex I and
GSH was observed from 0.5 to 24 hr after the administration of
a single dose of L-BOAA (Fig. 6B). It was only 48 hr after
administration of a single dose of L-BOAA that both GSH and
complex I returned to near control levels in both motor cortex and
lumbosacral cord (data not shown). Mitochondria from the motor
cortex (Fig. 7A) and lumbosacral region of spinal cord (Fig. 7B) of
mice treated with L-BOAA (10 mg/kg body weight) were incu-
bated in vitro with the thiol reductant dithiothreitol, and complex
I activity was assayed. Dithiothreitol completely reversed the
action of L-BOAA and restored the complex I activity to levels
comparable with those in corresponding controls (Fig. 7A,B),
indicating that the inhibition of enzyme activity was caused by
oxidation of thiols to protein disulfides.
Pretreatment of mice with the AMPA receptor antagonist
NBQX (30 mg/kg body weight, i.p.) 4 hr before L-BOAA admin-
istration completely abolished L-BOAA-induced (10 mg/kg body
weight, s.c.) complex I inhibition in the lumbosacral cord, indi-
cating that the mitochondrial enzyme loss was mediated through
downstream events of glutamate receptor activation (Fig. 8, top).
Interestingly, pretreatment of mice with the thiol antioxidant
Figure 7. Reversal by dithiothreitol of L-BOAA-mediated inhibition of
complex I in the motor cortex (A) and lumbosacral cord (B). Mice were
administered L-BOAA (10 mg/kg body weight, s.c.) and killed 0.5 hr after
dosing. Mitochondria, prepared by pooling the tissue from three animals,
were freeze-thawed three times, and complex I activity was assayed.
Thereafter, mitochondria from each sample were divided into two ali-
quots and incubated with and without dithiothreitol (3.5 mM) for 30 min
at 37°C. After the incubation, the samples were dialyzed, and the activity
of complex I was assayed before and after incubation with dithiothreitol.
Values are mean 6 SEM (n 5 5 samples wherein the mitochondria
prepared from three animals were pooled to make one sample). Asterisks
indicate values significantly different from control ( p , 0.05).
Figure 8. Effect of pretreatment of mice with NBQX (top) and a-lipoic
acid (bottom) on complex I activity in lumbosacral cord after L-BOAA
administration. Top, Two sets of mice were administered NBQX (30
mg/kg body weight, i.p.) and, after 4 hr, one set was dosed with L-BOAA
(10 mg/kg body weight, s.c.), whereas the other set received vehicle
(saline) alone. Bottom, Two sets of mice were pretreated with a-lipoic
acid (20 mg/kg body weight, s.c.) and, after 1 hr, one set was given
L-BOAA as described in the top panel. Another group of mice received
only L-BOAA, and the control animals received vehicle alone. The
animals were killed 24 hr after L-BOAA administration, the lumbosacral
segment of spinal cord was dissected out, and complex I activity
was estimated in the isolated mitochondria. Values are mean 6 SD (n 5
4 animals). Asterisks denote values significantly different from control
( p , 0.01).
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a-lipoic acid also abolished L-BOAA-mediated inhibition of com-
plex I activity (Fig. 8, bottom), indicating that thiol antioxidant
could potentially reverse the neurotoxic effects of L-BOAA.
Neurolathyrism is known to occur in humans after consump-
tion of at least 300 gm/d of the chickling peas from the plant
Lathyrus sativus for a period of at least 3 months (Streifler et al.,
1977). The concentration of L-BOAA in the pea varies from 0.1 to
2.5% (Roy, 1988) Assuming the average body weight of humans
as 60 kg and the least L-BOAA concentration in the pea as 0.1%
(w/w), the daily intake of L-BOAA would be 5 mg/kg body
weight. Male mice were administered 5 mg/kg body weight of
L-BOAA chronically for up to 40 d, after which one group of
animals was maintained untreated for an additional 15 d before
killing. Complex I activity in the lumbosacral cord (Fig. 9) showed
marked reduction after 5, 10, 20, and 40 d of L-BOAA exposure
(19, 29, 20, and 29% decrease), whereas in the motor cortex (Fig.
9), the activity was significantly decreased (48%) only after 40 d.
After withdrawal of L-BOAA, the complex I activity in the
lumbosacral cord recovered to control levels while remaining
significantly depressed in the motor cortex (Fig. 9).
Morphological evaluation was performed on the brain and
spinal cord of animals that received L-BOAA for 40 d (Fig.
10A–D). Pyramidal neurons of layers 3 and 5 in the motor cortex
revealed cytoplasmic vacuolation and swelling of the apical den-
drites. Similar pathology was also noted in the neurons of the
motor cranial nerve nuclei. In the spinal cord, the brunt of the
pathology was seen in the lumbar and sacral segments, with
relative sparing of the cervical and thoracic segments. The medial
and intermediate group of neurons corresponding to laminae 7
and 8 of the gray horn in the lumbar level of the spinal cord were
abnormal, whereas the lateral group of neurons (lamina 9 of the
gray horn) were relatively preserved. The spinal neurons showed
cytoplasmic vacuolation, dendritic swelling, and depletion of Nissl
substance. The neuronal contour was distorted significantly in
some by multiple vacuolation. However, the nucleus and nucleo-
lus were intact. Some of the vacuoles had a central, dark granule.
An increase in astrocytes was noted, many of them having a pale
watery nucleus and multiple obvious nucleoli, unlike in controls.
These astrocytes were seen as small clusters in the neuropil. In
mice, wherein L-BOAA was administered for 40 d and then
discontinued for 15 d, the pathological changes of neuronal vac-
uolation receded.
The effect of L-BOAA on mitochondrial complex I was gender-
specific. Exposure of brain slices from female mice to L-BOAA
had no effect on the complex I activity even at concentrations up
to 1 mM (data not shown). Administration of a single dose of
L-BOAA (10 mg/kg body weight, s.c.; Fig. 11A) or chronic expo-
sure to L-BOAA (5 mg/day, s.c; Fig. 11B) for 40 d did not have
any effect on the complex I activity in the motor cortex or
lumbosacral cord, whereas the activity was significantly inhibited
in similarly treated groups of male mice.
DISCUSSION
Animal models for neurolathyrism that mimic the progressive
degeneration of Betz cells in the motor cortex and the cortico-
spinal tract have not been reported. Monkeys fed 10- to 20-fold
higher doses than that necessary to produce irreversible neuro-
lathyrism in humans develop the initial signs of the disease as
evidenced by central motor deficits involving the corticospinal
tracts (Ludolph and Spencer, 1996). Administration of large
doses of the toxic principle L-BOAA to rodents, however, results
in seizures (ShashiVardan et al., 1997). Pathological effects in the
animal model of L-BOAA toxicity defined in the present study
share remarkable resemblance to the regiospecific effects seen in
the human disease. Selective inhibition of mitochondrial complex
I (Fig. 4) and pathological changes (Fig. 10) were seen in the
lumbosacral cord and the motor cortex after acute or chronic
exposure to L-BOAA with no apparent changes in all the other
regions of the CNS that were examined. The similarity with the
human disease was also seen in the gender-specific effects of
L-BOAA; the female mice were relatively resistant to the toxic
effects (Fig. 11). In humans, the incidence of neurolathyrism is
more common in men, whereas women are less prone to the
disease, although the intake of the chickling pea from Lathyrus
sativus is not significantly different (Roy, 1988). It has been
Figure 9. Effect of chronic administration of L-BOAA on complex I
activity in thoracic (top panel), lumbosacral segment of mouse spinal cord
(middle panel ) and motor cortex (top panel ). Mice were administered
L-BOAA (5 mg/kg body weight. s.c., daily) and killed on days 5, 10, 20,
and 40 (f–f). L-BOAA administration was stopped after 40 d, and the
animals were kept on normal diet for 15 d before killing. Control animals
received vehicle alone (F–F). After killing, the motor cortex (top), tho-
racic, and lumbosacral segments of the spinal cord (middle) were removed
and assayed for complex I activity. Values are mean 6 SD (n 5 6
animals). Asterisks denote values significantly different from control ( p ,
0.01).
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reported that pretreatment of cortical neuronal cultures with
estrogen protects them from excitotoxic insults when the cells
were challenged with glutamate (Behl et al., 1997). Although the
mechanism by which estrogens protect the neuronal cell is not
known, it is hypothesized that estrogen-like compounds, in gen-
eral, are able to protect the neurons from damage by oxidative
stress-mediated events.
The inhibition of complex I is a sensitive and selective index of
L-BOAA toxicity. In vitro, in brain slices, complex I is inhibited by
very low concentrations of L-BOAA in a dose- and time-
dependent manner, an effect not shared by other glutamate ago-
nists tested, with the exception of AMPA and glutamate, which
inhibit complex I at very much higher doses. We had earlier
reported that L-BOAA inhibits NADH-dehydrogenase activity in
vitro in mouse brain slices (Pai and Ravindranath, 1993), however,
measurement of rotenone-sensitive complex I activity is a more
sensitive and selective index of L-BOAA toxicity.
The mechanism of inactivation of complex I seems to be a
downstream event of L-BOAA action on excitatory amino acid
receptors, because the loss in complex I activity was blocked both
in vitro and in vivo by specific antagonists of AMPA receptor. The
neurotoxic effects of L-BOAA seem to be predominant in the
motor cortex and lumbosacral region of the spinal cord, and this
specificity does not seem to reflect the distribution of AMPA
receptors in the CNS. The observations made herein do seem to
suggest that hitherto undetected high-affinity binding sites for
L-BOAA may exist in the CNS. Earlier studies have shown that
administration of 14C-L-BOAA to rats resulted in maximal accu-
mulation of the radiolabel in the spinal cord (Rao, 1978). Never-
theless, the regions of the CNS affected by L-BOAA bear a
remarkable similarity to the regions affected in human forms of
the disease.
The results described herein provide the first evidence that
L-BOAA, an excitatory amino acid, can cause mitochondrial
dysfunction through inhibition of complex I in vivo in specific
regions of the CNS. Furthermore, the inhibition of complex I
activity was associated with oxidation of protein thiol groups in
complex I (Dupius et al., 1991), because the enzyme activity
rebounded after incubating the mitochondria with the thiol-
reducing agent dithiothreitol. From the experimental evidence
presented in this study, wherein the oxidative stress generated
(measured as loss of cellular antioxidant thiol GSH) followed the
inhibition of complex I activity (Fig. 6); loss of mitochondrial
complex I seems to be a primary event after exposure to
L-BOAA. But because selective cell populations are affected
within specific regions of the brain by L-BOAA, the measurement
of GSH in sagittal slices of whole brain as performed in the in
vitro experiments may not reflect subtle changes in the antioxi-
dant status in the targeted cells. However, the reversal of the loss
in complex I by thiol reductants seems to indicate that oxidative
stress and protein thiol oxidation may be primary events in
L-BOAA induced mitochondrial dysfunction. One of the down-
stream events of excessive stimulation of glutamate receptors is
the generation of reactive oxygen species leading to oxidative
stress-mediated cellular damage (Murphy et al., 1989).
Mitochondrial dysfunction has been recognized as a primary
event in glutamate neurotoxicity (Schinder et al., 1996), particu-
larly that mediated through NMDA receptors. The activation of
NMDA receptors leads to massive increase in intracellular cal-
cium, which results in the alteration in the mitochondrial mem-
brane potential and opening of the mitochondrial permeability
transition pore (White and Reynolds, 1996). However, pore-
opening through voltage-dependent channels is directly associ-
ated with an oxidation–reduction-sensitive dithiol, and the cross-
linking of the sulfhydryl groups increases the probability of the
mitochondrial permeability transition pore opening, an event that
can be blocked by the thiol reductant dithiothreitol (Petronilli et
al., 1994). Thus, the mitochondrial dysfunction caused through
mitochondrial permeability transition pore opening is also sensi-
tive to the oxidation of protein thiols in a manner similar to that
seen in the present study with reference to the inhibitory effect of
L-BOAA on complex I. We have earlier shown that brain mito-
chondria (Ravindranath and Reed, 1990) are severalfold more
vulnerable to oxidative stress-mediated damage as compared with
liver mitochondria (Olafsdottir and Reed, 1988), and the major
consequence of oxidative stress on brain mitochondria is the
formation of protein–glutathione-mixed disulfide (rather than
increase in levels of oxidized GSH, GSSG as seen in liver mito-
Figure 10. Lumbar cord (A, B) and motor cortex (C, D)
sections from control animals and those treated with
L-BOAA (5 mg/kg body weight for 40 d). A, Anterior horn
neurons of the lumbar spinal cord from control animal. B,
Similar section as A from animals chronically administered
L-BOAA; anterior horn neurons show cytoplasmic vacuola-
tion (arrowheads), whereas the nucleus and nucleolus are
relatively well preserved. The vacuolation of the apical den-
drites resulting in distortion of the neuronal contour is seen
at higher magnification in inset I; inset II depicts the pale area
in cytoplasm of the large neuron that extends along the
dendrite and indents the adjacent cell. C, Cortical pyramidal
neurons in layer V of motor cortex from control mouse. D, A
similar section as C from L-BOAA-treated mouse showing
vacuolation and clearing along the apical dendrites (arrow-
heads) and depletion of Nissl substance in the pyramidal
neurons. Scale bar, 25 mm.
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chondria). Taken together these studies demonstrate the vulner-
ability of brain mitochondrial proteins to oxidative modification
through formation of mixed disulfides.
The involvement of excitatory amino acids in the pathogenesis
of motor neuron disease has been demonstrated both in sporadic
cases (Rothstein et al., 1990) and in chemically induced forms of
the disease (Spencer et al., 1986, 1987). More recent develop-
ments include the discovery of mitochondrial dysfunction in a
variety of neurodegenerative disorders, including motor neuron
disease (Chang et al., 1995; Mizuno et al., 1995). This study
provides evidence indicating a mechanism for neurodegeneration
through mitochondrial dysfunction chemically induced through
excitatory amino acids. Increased glutaminergic activity has been
shown to be associated with Parkinson’s disease (Verma and
Kulkarni, 1995), and glutamate antagonists (Stauch Slusher et al.,
1995) have been shown to alleviate Parkinsonism in experimental
animals. Recent hypotheses on role of excitatory amino acids in
pathogenesis of sporadic motor neuron disease have also resulted
in new putative therapies that include anti-excitotoxicity agents
(Rothstein, 1996). Although the loss of complex I activity has
been demonstrated in Parkinson’s disease patients (Parker et al.,
1989); the present study indicates a similar dysfunction in chem-
ically induced motor neuron disease, in experimental animals. It
remains to be seen if similar dysfunction occurs in humans in
sporadic forms of the disease.
In conclusion, the present investigation demonstrated that ex-
citatory amino acids like L-BOAA cause mitochondrial dysfunc-
tion in selected regions of the CNS that can be reversed in vitro by
thiol reductants. The results indicate an initiating role for oxida-
tive stress and the potential importance of maintaining protein
thiol homeostasis in brain through administration of thiol
antioxidants.
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